Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 217-223

  Fontes, Joao D ^a,b   Yamamoto, Jennifer F ^a   Larson, Martin G ^a,c   Wang, Na ^c   Dallmeier, Dhayana ^a,b   Rienstra, Michiel ^a,d   Schnabel, Renate B ^a,e   Vasan, Ramachandran S ^a,b   Keaney, John F ^f   Benjamin, Emelia J ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boston University   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Biological markers; Inflammation; Longitudinal studies

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE 2; OSTEOPROTEGERIN; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SMOKING; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; ISOPROSTANES; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; MIDDLE AGED; OSTEOPROTEGERIN; P-SELECTIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; VASCULITIS;

EID: 84876813588     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.019     Document Type: Article

References (51)

1. Wilson P.W., Nam B.H., Pencina M., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005, 165:2473-2478.
2. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007, 49:432-438.
3. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
4. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
5. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
6. Kugiyama K., Ota Y., Takazoe K., et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999, 100:1280-1284.
7. Pradhan A.D., Rifai N., Ridker P.M. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002, 106:820-825.
8. Chen T.H., Gona P., Sutherland P.A., et al. Long-term C-reactive protein variability and prediction of metabolic risk. Am J Med 2009, 122:53-61.
9. Farzadfar F., Finucane M.M., Danaei G., et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011, 377:578-586.
10. Danaei G., Finucane M.M., Lin J.K., et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011, 377:568-577.
11. Finucane M.M., Stevens G.A., Cowan M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
12. Kannel W.B., Feinleib M., McNamara P.M., et al. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979, 110:281-290.
13. Splansky G.L., Corey D., Yang Q., et al. The third generation cohort of the national heart, lung, and blood institute's Framingham heart study: design, recruitment, and initial examination. Am J Epidemiol 2007, 165:1328-1335.
14. Schnabel R., Larson M.G., Dupuis J., et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008, 51:1651-1657.
15. Schnabel R.B., Lunetta K.L., Larson M.G., et al. The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ Cardiovasc Genet 2009, 2:229-237.
16. Schnabel R., Larson M.G., Dupuis J., et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008.
17. Schnabel R.B., Larson M.G., Yamamoto J.F., et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009, 104:92-96.
18. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
19. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.
20. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97:425-428.
21. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
22. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, sICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997, 96:4219-4225.
23. Schwedhelm E., Bartling A., Lenzen H., et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004, 109:843-848.
24. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
25. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
26. Ridker P.M., Buring J.E., Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001, 103:491-495.
27. Suzuki T., Solomon C., Jenny N.S., et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail 2009, 2:429-436.
28. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
29. Nambi V., Hoogeveen R.C., Chambless L., et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2009, 40:376-381.
30. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
31. Halvorsen B., Lund Sagen E., Ueland T., et al. Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease. Scand J Clin Lab Invest 2007, 67:604-611.
32. Levitzky Y.S., Guo C.Y., Rong J., et al. Relation of smoking status to a panel of inflammatory markers: the Framingham Offspring. Atherosclerosis 2008, 201:217-224.
33. Pou K.M., Massaro J.M., Hoffmann U., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007, 116:1234-1241.
34. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005, 69:29-35.
35. Festa A., D'Agostino R., Williams K., et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001, 25:1407-1415.
36. Robker R.L., Collins R.G., Beaudet A.L., et al. Leukocyte migration in adipose tissue of mice null for sICAM-1 and Mac-1 adhesion receptors. Obes Res 2004, 12:936-940.
37. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 2003, 289:1799-1804.
38. Selvin E., Paynter N.P., Erlinger T.P. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31-39.
39. Sakai A., Kume N., Nishi E., et al. P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol 1997, 17:310-316.
40. Ivandic B., Castellani L.W., Wang X.P., et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999, 19:1284-1290.
41. Li H., Cybulsky M.I., Gimbrone M.A., et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993, 13:197-204.
42. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
43. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N.Engl.J Med 2008, 359:2195-2207.
44. Bautista L.E. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003, 17:223-230.
45. Ridker P.M., Danielson E., Rifai N., et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006, 48:73-79.
46. Dehghan A., Dupuis J., Barbalic M., et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011, 123:731-738.
47. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100:713-716.
48. van der Vaart H., Postma D.S., Timens W., et al. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004, 59:713-721.
49. Keaney J.F., Larson M.G., Vasan R.S., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434-439.
50. Murabito J.M., Keyes M.J., Guo C.Y., et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study. Atherosclerosis 2009, 203:509-514.
51. Currie C.J., Poole C.D., Conway P. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008, 94:457-462.